Finally, Europe gets its first probiotic health claim approved. Could this pave the way to an EU claim?
DuPont is now the first ingredient company with a probiotic health claim in Europe, the company announced yesterday. Switzerland’s Federal Food Safety and Veterinary Office approved a claim for DuPont Danisco’s Howaru Bifidobacterium lactis HN019 strain for supporting digestive health.
Specifically, Howaru Bifidobacterium lactis HN019 improves regularity by reducing transit time-meaning that it cuts down the amount of time required to excrete food once consumed.
Is this Switzerland claim a step in the right direction to an EU-wide health claim? With the EU European Food Safety Authority (EFSA) continuing to reject probiotic claims-a point of severe frustration for many probiotic marketers and ingredient suppliers-DuPont certainly hopes so. The company says it is continuing its endeavors for an EU claim.
“Despite the regulatory challenges in Europe, DuPont continues to deliver scientifically proven data on the efficacy of our probiotics,” says Peggy Steele, global business director, food and beverage probiotics, DuPont Nutrition & Health. “DuPont now has a positive claim within Switzerland, and we hope to soon have a broader positive claim within the EU.”
Where EFSA is concerned, DuPont “has carefully studied EFSA’s position on health claims and has worked proactively to develop new science to support our claims,” says Steele. “At the same time, we have accelerated our studies in an effort to generate science that meets EFSA’s guidelines/criteria.”
DuPont is hoping this will be a win all around. “The Swiss authority approval is a good signal on the quality of our dossier for Howaru Bifido HN019,” says Steele.
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
Recent study compares the effectiveness of two probiotic products on colicky infants
October 31st 2024The study compared AB-Biotics and Kaneka Probiotics’ probiotic formulation of Bifidobacterium longum KABP®-042 and Pediococcus pentosaceus KABP®-041 to Lactobacillus reuteri DSM17938 (LR) from Biogaia.